Hyperphosphatemia Raises Coronary Artery Calcification (CAC) Risk in Peritoneal Dialysis
Study also shows that serum phosphorus levels are associated with nutritional intake and dialysis adequacy.
PHILADELPHIA—Hyperphosphatemia is an independent risk factor for coronary artery calcification (CAC) progression in patients undergoing peritoneal dialysis (PD), according to a Chinese study presented at Kidney Week 2014.
Additionally, serum phosphorus levels are associated with nutritional intake and adequacy of dialysis treatment.
Da Shang and colleagues in the Division of Nephrology at Fudan University in Shanghai, China, looked at 207 adults with end-stage renal disease (ESRD) who had been on PD for more than 6 months as part of a prospective, observational cohort study. They were divided into either slow or rapid progression groups (131 patients and 76 patients, respectively) depending on the velocity of CAC progression. The median interval of the first and last CAC score measurements was 24.6 months.
On multivariate analysis, hyperphosphatemia was associated with higher transferrin, serum albumin, and normalized protein catabolic rate (nPCR), as well as lower hemoglobin, residual creatinine clearance (Ccr), and PD Ccr.
Age, body mass index, and serum phosphorus were found to be independent risk factors of CAC progression.
“These results provide important information for the clinical management of ESRD patients,” the authors concluded.